This week, we’ll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we’ll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we’ll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students.

Coverage of stories discussed this week on ascopost.com:

Extended Follow-up of CheckMate 214: Nivolumab/Ipilimumab vs Sunitinib as First-Line Treatment for Advanced RCC

Key Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer Types

Exposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students